Abstract: Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML). complete remission rates are close to 60% to 70%. and relapses occur in >40% of cases. Here. https://www.sukrensi.com/flash-sale-Ribavirin-500MG-R0077-500MG-p9633-big-savings/